Jeannine O'Connor Email
Associate Director, Professional Relations & Medical Affairs Operations . CTI BioPharma
Seattle, WA
Locationj***************@zambongroup.com
Primary EmailHow to contact Jeannine O'Connor
Join and see Jeannine's contact info for free!Current Roles
Employees:
257Revenue:
$39.8MAbout
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. VONJO^TM is a trademark of CTI BioPharma Corp.CTI BioPharma Address
3101 Western Ave., #600Seattle, WA
United States